The ASAM National Practice Guideline Special Populations Webinar (December)
- Registration Closed
This special populations webinar series follows the National Practice Guideline overview webinar which outlined the recommendations from ASAM's National Practice Guideline for the Use of Medications in the Treatment of Opioid Use Disorders, which is the first guideline to include all medications to treat opioid use disorder.
The treatment of adolescents with opioid use disorder presents many unique medical, legal, and ethical dilemmas that may complicate treatment. Given these unique issues, adolescents with opioid use disorder often benefit from services designed specifically for them. The Adolescents Webinar will provide an overview of the recommendation and in-depth information treating adolescents from ASAM's National Practice Guideline.
This webinar is primarily intended for clinicians involved in evaluating patients and providing authorization for pharmacological treatments at any level.
At the conclusion of the webinar, participants should be able to:
- Recognize epidemiology of opioid use disorder and the treatment gap among patients misusing opioids and heroin.
- Summarize the guideline's treatment recommendations for special populations and discuss how they should be used in practice.
- Identify the fundamental components of an OUD patient assessment and diagnosis for special populations with opioid use disorders.
- Discuss the unique needs and treatment recommendations for adolescents.
The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
ASAM designates this live activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Addiction Medicine (ABAM) MOC:
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of .75 AMA PRA Category 1 Credits™.
|Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO, Chair||None|
Catherine Friedman, MD, Vice Chair, Reviewer
|Noel Ilogu, MD, MRCP||None|
|Herbert L. Malinoff, MD, FACP, FASAM||None|
|Edwin A. Salsitz, MD, FASAM, Reviewer||None|
|John C. Tanner, DO, FASAM, CCFC, MRO||
Reckitt-Benckiser: Honorarium, Speaker
Orexo: Honorarium, Speaker
BDSI: Honorarium, Speaker & Consultant
|Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO||None|
|Margaret A. E. Jarvis, MD, FASAM||
Geisinger Health System: Salary, Medical Director
US Preventive Health: Dividend, Stockholder
Hoffspiegel and Associates: Fees, Expert Witness
Up-to-Date: Royalties, Author
|Robert J. Roose, MD, MPH||Health New England, Inc.: Honorarium, Behavioral Health Advisory Committee, Associate Medical Director|
|Marc Fishman, MD, DFASAM||
Maryland Treatment Centers: Employment, Ownership Interest includes stock, stock options, patent or other intellectual property
US World Meds: Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received
|Aaron D. Fox, MD, MS||None|
|Brian Hurley, MD, MBA, DFASAM||None|
|Yngvild Olsen, MD, MPH, FASAM||None|
|Tricia Wright, MD, MS, FACOG, FASAM||None|
Marc J. Fishman
Marc Fishman MD is board certified in addiction psychiatry and addiction medicine. A faculty member of the Johns Hopkins University School of Medicine, he is Medical Director and CEO of Maryland Treatment Centers, a regional behavioral health care provider, with inpatient and outpatient facilities for adolescents and adults. His clinical specialties include treatment of drug-involved and dual-diagnosis adolescents, opioid dependence in adolescents and adults, and co-occurring disorders. He has been principal investigator or collaborator for several NIDA- and CSAT-funded projects to improve and evaluate adolescent treatment, as well as pharmacotherapy trials in adults. He is the author of numerous articles and book chapters on addiction treatment, and lectures widely on a variety of topics including adolescent treatment, youth opioid treatment, placement and treatment matching strategies. Dr. Fishman served as a co-editor for the most recent editions of ASAMs Patient Placement Criteria, leading the adolescent section, and served as the chief editor for the ASAM PPC Supplement on Pharmacotherapies for Alcohol Use Disorders. He is the chair of the Adolescent Committee for ASAM. He is a Past President of the Maryland Society of Addiction Medicine.